Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-05-02
2006-05-02
Schwadron, Ronald B. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S143100, C424S144100, C424S154100, C424S173100, C424S801000, C424S809000, C530S387300, C530S387100, C530S388200, C530S388220, C530S385000, C530S867000, C530S866000
Reexamination Certificate
active
07037496
ABSTRACT:
Chimeric antibodies for CD4 receptor comprising a variable or antigen binding region of a non-human origin specific for CD4 receptor and a constant region of human origin are disclosed. These antibodies are useful as therapeutic agents for auto-immune disorders.
REFERENCES:
patent: 4381295 (1983-04-01), Kung et al.
patent: 4695459 (1987-09-01), Steinman et al.
patent: 0 125 023 (1984-11-01), None
patent: 0 171 496 (1986-02-01), None
patent: 0 173 494 (1986-03-01), None
patent: 0 200 412 (1986-12-01), None
patent: 0 240 344 (1987-10-01), None
patent: 0 365 209 (1990-04-01), None
patent: 0 394 827 (1990-10-01), None
patent: 0 511 308 (1992-11-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 88/09181 (1988-12-01), None
patent: WO 90/12868 (1990-11-01), None
patent: WO 91/09966 (1991-07-01), None
patent: WO 91/09967 (1991-07-01), None
Taylor et al. , Chapter T4.14, from: “Leukocyte Typing III, White Cell Differentiation Antigens”, Oxford University Press, 1987, pp. 234-237.
Kong, Y. M., et al., “Pathogenic Mechanisms in Murine Autoimmune Thyroiditis: Short- and Long-Term Effects of in vivo depletion of CD4+ and CD8+ Cells,”Clin. Exp. Immunol., 77:428-433 (1989).
Cobbold, S.P., et al., “Therapy with Monoclonal Antibodies by Elimination of T-Cell Subsets in vivo,”Nature, 312:548-551 (1984).
Mudgett-Hunter, M., et al., “Binding and Structural Diversity Among High-Affinity Monoclonal Anti-Digoxin Antibodies,”Molecular Immunology, 22(4):477-488 (1985).
Playfair, J.H.L., “Antigen-Antibody Interaction and Immune Complexes,” InImmunology At a Glance, (Blackwell Scientific Publication; London), Chapter 14 (1984).
Evans, R.L., et al., “Thymus-Dependent Membrane Antigens in Man: Inhibition of Cell-Mediated Lympholysis by Monoclonal Antibodies to TH2Antigen,”Proc. Natl. Acad. Sci., 78(1):544-548 (1981).
Matthews, T.J., et al., “AIDS Vaccines”,Scientific American, 259(4):98-105 (1988).
van Oosten, B. W., et al., “Treatment of Multiple Sclerosis with the Monoclonal Anti-CD4 Antibody cM-T412: Results of a Randomized, Double-Blind, Placebo-Controlled, MR-Monitored Phase II Trial,”Neurology, 49:351-357 (1997).
Moreland, L. W., et al., “Experience with a Chimeric Monoclonal Anti-CD4 Antibody in the Treatment of Refractory Rheumatoid Arthritis,”Clinical and Experimental Rheumatology, 11(Suppl. 8):S153-S159 (1993).
Gill, H.S., et al., “In vivo Inhibition by a Monoclonal Antibody to CD4+T Cells of Humoral and Cellular Immunity in Sheep,”Immunology, 77:38-42 (1992).
Bushell, A., et al., “Transplantation Tolerance Induced by Antigen Pretreatment and Depleting Anti-CD4 Antibody Depends on CD4+T Cell Regulation During the Induction Phase of the Response,”Eur. J. Immunol., 25:2643-2649 (1995).
Matloubian, M., et al., “CD4+Cells are Required to Sustain CD8+Cytotoxic T-Cell Responses During Chronic Viral Infection,”Journal of Virology, 68(12):8056-8063 (1994).
Canva-Delcambre, V., et al., “Treatment of Severe Crohn's Disease with Anti-CD4 Monoclonal Antibody,”Ailment Pharmacol. Ther., 10:721-727 (1996).
van Montfrans, C., et al., “Immunotherapy of Crohn's Disease,”Mediators of Inflammation, 7:149-152.
Reiter, C., et al., “Treatment of Rheumatoid Arthritis with Monoclonal CD4 Antibody M-T151. Clinical Results and Immunopharmacologic Effects in an Open Study, Including Repeated Administration,”Arthritis and Rheumatism, 34(5):525-536 (1991).
Moreland, L. W., et al., “Use of a Chimeric Monoclonal Anti-CD4 Antibody in Patients with Refractory Rheumatoid Arthritis,”Arthritis and Rheumatism, 36(3):307-318 (1993).
Boehringer Mannheim Biochemicals Catalogue, p. 328, 1987/1988.
Boehringer Mannheim Biochemicals Catalogue, p. 109, 1989.
Genbank Accession No. PH1224, “Ig Kappa Chain Precursor V Region (M-T151)—Mouse (fragment),” (1999) [online], [retrieved on Apr. 10, 2000]. Retreived from www.ncbi.nlm.nih.gov:80.
Genbank Accession No. PH1225, “Ig Heavy Chain Precursor V Region (M-T151)—Mouse (fragment),” (1999) [online], [retrieved on Apr. 10, 2000]. Retreived from www.ncbi.nlm.nih.gov:80.
Genbank Accession No. S19970, “Ig Kappa Chain V Region (M-T151)—Mouse (fragment),” (1999) [online], [retrieved on Apr. 10, 2000]. Retrieved from www.ncbi.nlm.nih.gov:80.
Genbank Accession No. S19963, “Ig Heavy Chain V Region (M-T151)—Mouse)fragment),” (1996) [online], [retrieved on Apr. 10, 2000]. Retrieved from www.ncbi.nlm.nih.gov:80.
Genbank Accession No. CAA46223, “Alpha CD4 mAb Immunoglobulin Light Chain VJ Region [Mus musculus],” (1997) [online], [retrieved on Apr. 10, 2000]. Retrieved from www.ncbi.nlm.nih.gov:80.
Genbank Accession No. CAA46215, “Alpha CD4 mAb Immunoglobulin Heavy Chain VDJ Region [Mus Musculus],” (1997) [online], [retrieved on Apr. 10, 2000]. Retrieved from www.ncbi.nlm.nih.gov:80.
Genbank Accession No. AAB24319, “Anti-CD4 mAb M-T151 Variable Region Heavy Chain <J4, Chimeric Antibody> [Mice, Hybridoma Cells, Peptide Partial, 139 aa],” (1993) [online], [retrieved on Apr. 10, 2000]. Retrieved from www.ncbi.nlm.nih.gov:80.
Genbank Accession No. AAB24318, “Anti-CD4 mAb M-T151 Variable Region Light Chain [J2, Chimeric Antibody] [Mice, Hybridoma Cells, Peptide Partial, 127 aa],” (1993) [online], [retrieved on Apr. 10, 2000]. Retrieved from www.ncbi.nlm.nih.gov:80.
Genbank Accession No. X65095, “M. musculus mRNA for IG Light Chain VJ Region (M-T151),” (1997) [online], [retrieved on Apr. 10, 2000]. Retrieved from www.ncbi.nlm.nih.gov:80.
Genbank Accession No. X65087, “M. musculus mRNA for IG Heavy Chain VDJ Region (M-T151),” (1997) [online], [retrieved on Apr. 10, 2000]. Retrieved from www.ncbi.nlm.nih.gov:80.
Genbank Accession No. S50263, “Ig VH=anti-CD4 mAb M-T151 Variable Region Heavy Chaim <J4, Chimeric Antibody> [Mice, Hybridoma Cells, mRNA Partial, 417 nt],” (1993) [online], [retrieved on Apr. 10, 2000]. Retrieved from www.ncbi.nlm.nih.gov:80.
Genbank Accession No. S50261, “Ig VL=anti-CD4 mAb M-T151 Variable Region Light Chain <J2, Chimeric Antibody> [Mice, Hybridoma Cells, mRNA Partial, 381 nt],” (1993) [online], [retrieved on Apr. 10, 2000]. Retrieved from www.ncbi.nlm.nih.gov:80.
Declaration of Dr. Christian Reiter executed on Nov. 2, 1994, filed in opposition proceeding in EP 0 511 308 (Reference AL3).
Declaration of Dr. Margaret R. Dalesandro executed on Jul. 1, 1998, filed in opposition proceeding in EP 0 511 308 (Reference AL3).
Sun, L.K., et al., “Chimeric Antibody with Human Constant Regions and Mouse Variable Regions Directed Against Carcinoma-Associated Antigen 17-1A,”Proc. Natl. Acad. Sci. USA, 84:214-218 (1987).
Morrison, S.L., et al., “Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains,”Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984).
Landau, N.R., et al., “The Envelope Glycoprotein of the Human Immunodeficiency Virus Binds to the Immunoglobulin-like Domain of CD4,”Nature, 334:159-162 (1988).
Wang, J., et al., “Atomic Structure of a Fragment of Human CD4 Containing Two Immunoglobulin-like Domains,”Nature, 348:411-418 (1990).
Ryu, S.E., et al., “Crustal Structure of an HIV-binding Recombinant Fragment of Human CD4,”Nature, 348:419-426 (1990).
Sattentau, Q.J., et al., “Epitopes of the CD4 Antigen and HIV Infection,”Science, 234:1120-1123 (1986).
Peterson, A., et al., “Genetic Analysis of Monoclonal Antibody and HIV Binding Sites on the Human Lymphocyte Antigen CD4,”Cell, 54:65-72 (1988).
Sattentau, Q.J., et al., “Structural Analysis of the Human Immunodeficiency Virus-binding Domain of CD4,”J. Exp. Med., 170:1319-1334 (1989).
Ashkenazi, A., et al., “Mapping the CD4 Binding Site for
Ghrayeb John
Knight David M.
Looney James E.
Centocor, Inc.
Hamilton Brook Smith & Reynolds P.C.
Schwadron Ronald B.
LandOfFree
Chimeric immunoglobulin for CD4 receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric immunoglobulin for CD4 receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric immunoglobulin for CD4 receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3528420